RAPT Therapeutics, Inc. (RAPT) Financial Ratios
8 years of historical data (2017–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.56
↓-60% vs avg
5yr avg: 3.88
30Y Low0.3·High8.2
ROE
↓
-77.1%
↑-36% vs avg
5yr avg: -56.6%
30Y Low-77%·High-39%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RAPT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
RAPT Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $296M | $64M | $953M | $644M | $1.0B | $477M | $603M | — | — |
| Enterprise Value | $130M | $-100840405 | $912M | $614M | $982M | $452M | $525M | — | — |
| P/E Ratio → | -2.28 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 421.94 | 263.85 | 94.54 | — | — | — |
| P/B Ratio | 1.56 | 0.34 | 6.48 | 2.63 | 5.40 | 4.58 | 8.24 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RAPT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 402.32 | 257.55 | 89.59 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
RAPT Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -77.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating Margin | — | — | — | -5618.5% | -1815.1% | -1055.4% | — | — | — |
| Net Profit Margin | — | — | — | -5490.4% | -1814.9% | -1049.0% | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -77.1% | -77.1% | -59.6% | -38.9% | -47.6% | -59.7% | -62.7% | -4538.2% | — |
| ROA | -62.8% | -62.8% | -53.1% | -36.1% | -43.6% | -52.0% | -55.8% | -60.2% | -57.8% |
| ROIC | -155.7% | -155.7% | -59.3% | -34.1% | -43.0% | -106.4% | -41.7% | -34.6% | — |
| ROCE | -79.3% | -79.3% | -63.0% | -38.9% | -46.7% | -58.3% | -62.2% | -65.9% | -62.2% |
RAPT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $170M exceeds total debt of $4M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.05 | 0.04 | — | — | — | 2.52 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.87 | -0.28 | -0.12 | -0.13 | -0.24 | -1.06 | 1.52 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($170M) exceeds total debt ($4M)
RAPT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
RAPT Therapeutics, Inc.'s current ratio of 4.87x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 17.77x to 4.87x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.87 | 4.87 | 7.41 | 17.77 | 20.11 | 9.84 | 8.70 | 14.01 | 14.85 |
| Quick Ratio | 4.87 | 4.87 | 7.41 | 17.77 | 20.11 | 9.84 | 8.70 | 14.01 | 14.85 |
| Cash Ratio | 4.78 | 4.78 | 7.28 | 17.51 | 19.77 | 9.50 | 8.36 | 13.74 | 14.63 |
| Asset Turnover | — | — | — | 0.01 | 0.02 | 0.04 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
RAPT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
RAPT Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $5M | $5M | $4M | $3M | $3M | $3M | $3M | $3M |
Peer Comparison
Compare RAPT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RAPTYou | $296M | -2.3 | — | — | — | — | -77.1% | -155.7% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ARVN | $656M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 RCUS | $3B | -7.9 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 INCY | $20B | 15.6 | 11.8 | 14.7 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
 ABBV | $363B | 86.5 | 15.1 | 20.4 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 LGND | $5B | -1057.0 | 356.7 | 59.1 | 93.4% | -13.5% | -0.5% | -2.3% | 0.6 |
 CLDX | $2B | -8.8 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
 DAWN | $2B | -20.7 | — | — | 89.1% | -80.8% | -22.7% | -30.5% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See RAPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RAPT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RAPT vs KYMR
Side-by-side business, growth, and profitability comparison vs Kymera Therapeutics, Inc..
Start ComparisonRAPT — Frequently Asked Questions
Quick answers to the most common questions about buying RAPT stock.
What is RAPT Therapeutics, Inc.'s P/E ratio?
RAPT Therapeutics, Inc.'s current P/E ratio is -2.3x. This places it at the 50th percentile of its historical range.
What is RAPT Therapeutics, Inc.'s ROE?
RAPT Therapeutics, Inc.'s return on equity (ROE) is -77.1%. The historical average is -57.6%.
Is RAPT stock overvalued?
Based on historical data, RAPT Therapeutics, Inc. is trading at a P/E of -2.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.